Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Review5021 has been discontinued.
View all Adrenergic α<sub>2</sub> Receptors products.TC-G 1000 is a potent and selective α2D-adrenoceptor agonist (Ki values are 8.6 pM and 110 nM for rat α2D and α1 receptors respectively and 25, 26 and 100 nM for human α2A, α2C and α2B receptors respectively. Exhibits analgesic activity in a mouse model of abdominal irritation. Orally active.
分子量 | 346.4 |
公式 | C13H14N2S.C4H4O4 |
储存 | Desiccate at RT |
纯度 | ≥98% (HPLC) |
CAS Number | 245744-18-7 |
PubChem ID | 90488997 |
InChI Key | OPCJPAYHMCWCGW-BTJKTKAUSA-N |
Smiles | CC1=C2C(C(C3=CNC=N3)=CCC2)=C(C)S1.O=C(\C=C/C(O)=O)O |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
参考文献是支持产品生物活性的出版物。
Ross et al (2000) α2 adrenoceptor agonists as potential analgesic agents. 2. Discovery of 4-(4-Imidazo)-1,3-dimethyl-6,7-dihydrothianaphthene as a high-affinity ligand for the α2D adrenergic receptor. J.Med.Chem. 43 1423 PMID: 10715142
关键词: TC-G 1000, TC-G 1000 supplier, TC-G1000, potent, selective, adrenergic, receptors, agonists, alpha2d, alpha1, alpha2a, alpha2b, alpha2c, α2d, α2a, α1, α2b, α2c, adrenoceptors, Adrenergic, Alpha-2, Receptors, 5021, Tocris Bioscience
目前没有该产品的评论。 Be the first to review TC-G 1000 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.